Selective cTACE Trial in HCC: 48 Patient Outcomes from a 2021-2023 Japan Study

Clinical trial data from a multicenter phase II study (jRCTs052200095) evaluating selective conventional transarterial chemoembolization for hepatocellular carcinoma. The dataset includes results for 48 patients enrolled between January 2021 and June 2023, with primary endpoints of complete response rates at 1 and 3 months. It was uploaded by figshare admin karger and is licensed under CC-BY-4.0.

Use Cases

• Analyze complete response rates for cTACE treatment based on the reported 97.8% CR rate at 1 and 3 months.
• Evaluate the safety profile of the emulsification device based on the incidence of serious adverse events like elevated AST and ALT.
• Compare treatment outcomes with historical controls based on the exploratory analyses mentioned in the description.
• Assess liver function deterioration based on the reported 17.8% proportion of patients with ALBI grade increase.

Strengths

• Data originates from a defined multicenter phase II clinical trial (jRCTs052200095) with a specific protocol.
• Includes results for 48 patients in the safety set and 45 patients for efficacy analysis, providing a clear cohort size.
• Reports specific, quantified outcomes including a 97.8% complete response rate and adverse event percentages (e.g., 50.0% elevated AST).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for certain analytical tasks.
• Data may reflect geographic and temporal bias inherent to the trial conducted in Japan between 2021 and 2023.

Provenance

Source

figshare admin karger

Collection Method

Data collected from a multicenter phase II clinical trial (jRCTs052200095).

Time Range

January 2021 to June 2023

Freshness

Last updated 2026-05-11 05:58:22; freshness should be verified.

Geography

Japan